EpiCept treatment improves leukemia survival rate

December

Shares of EpiCept Corp. rose 3.2 percent after the Tarrytown-based biotech company reported that trials of its Ceplene cancer treatment showed an improved survival rate in leukemia patients.

EpiCept is seeking a commercial partner to market Ceplene in Europe to adults with acute myeloid leukemia following regulatory approval to market the treatment in 27 European Union states, as well as Iceland, Liechtenstein and Norway. The company also said that it will intends to pursue regulatory approvals for Ceplene in the United States and Canada.

“Delaying and preventing relapse in (acute myeloid leukemia) patients who achieve complete remission is critical to their long-term survival,” said Jack Talley, chief executive officer of EpiCept.

Shares of the company rose 2 cents yesterday to 64 cents.

This entry was posted on Thursday, December 4th, 2008 at 2:27 pm by Jay Loomis.
You can follow any responses to this entry through the RSS 2.0 feed.
Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.